Estudos científicos, publicações e artigos sobre medicamentos oncológicos para o tratamento de pacientes.

Publicações

Trabalhos ReceptaBio

Apresentações em Congressos

Anti-LeY monoclonal antibody (mAb) hu3S193 (Rebmab100) in patients with advanced platinum resistant / refractory (PRR) ovarian cancer (OC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC). Smaletz O, Diz, M. D. P, Carmo C. C, Sabbaga J, Cunha GF, Azevedo SJ, Maluf FC, Barrios CH, Costa RL, Fontana AG, Alves VA, Moro AM, Scott AM, Hoffman EW, Old LJ. Journal of Clinical Oncology 29, no. 15_suppl. 5078-5078.

Anti-LeY monoclonal antibody (mAb) hu3S193 as consolidation therapy for patients (pts) with relapsing platinum sensitive ovarian cancer (OC) after achieving a second complete response (2CR). Smaletz O, Ismael G, Diz MDPE, Nascimento IL, Wiermann ALG, Cunha GF, Azevedo SJ, Alves VA, Moro AM, Yeda FP, dos Santos ML, Majumder I, Hoffman EW. Journal of Clinical Oncology 2017 35:15_suppl, e17039-e17039.

Humanized anti-NaPi2b Monoclonal Antibody-Cell Line Generation. Yeda FP, Santos, ML, Tsuruta LR, Horta, BB, Pimenta Jr. AA, Ritter, G, Moro, AM.

Lewis B (LeB) antigen expression in colorectal carcinoma: a tissue microarray (TMA) study. Espirito Santo KS, Soares IC, Scapulatempo C, Wakamatsu A, Okamoto OK, Alves VAF. J Bras Patol, 2007, 43 (5):89 (09.46).

Immunohistochemical characterization of ovarian carcinoma with monoclonal antibody MX35. Soares IC, Espírito Santo KS, Wakamatsu A, Réssio RA, Souza SJ, Souza JES, Okamoto OK, Alves VAF. Histopathology 2008,53 (Suppl. 1):180-181 (410) JCR: 3.2160.

Top